Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1999 Feb;75(1):49-54.
doi: 10.1136/sti.75.1.49.

Use of antiviral treatment and prophylaxis is unlikely to have a major impact on the prevalence of herpes simplex virus type 2

P J White  1 , G P Garnett
Affiliations

Use of antiviral treatment and prophylaxis is unlikely to have a major impact on the prevalence of herpes simplex virus type 2

P J White et al. Sex Transm Infect. 1999 Feb.

Abstract

Background: Genital infection with herpes simplex virus (HSV) is common and can cause severe morbidity, over many years in some cases. Aciclovir provides suppressive therapy but there is debate over the effects of its use on the spread of infection.

Objectives: To explore the influence of the natural history of genital HSV and the impact of antiviral therapy.

Methods: A simple mathematical model of HSV-2 transmission dynamics was developed, and parameter values estimated from published data.

Results: The relative durations of the risk of transmitting HSV-2 and the duration of therapy generate a non-linear relation between the duration of antiviral therapy and the reduction in prevalence infection. If there is a wide distribution of risk of HSV-2 transmission over the course of an infection then practicable aciclovir use is unlikely to have any great impact on disease transmission dynamics.

Conclusions: There are still many uncertainties in the transmission dynamics of HSV-2. In particular, infectiousness over the course of an infection requires more detailed exploration. To have a significant impact on the prevalence of HSV-2 aciclovir use would have to be widespread and for a long duration.

PubMed Disclaimer

References

    1. JAMA. 1988 Oct 21;260(15):2227-30 - PubMed
    1. Ann Intern Med. 1992 Mar 15;116(6):433-7 - PubMed
    1. Arch Intern Med. 1996 Aug 12-26;156(15):1729-35 - PubMed
    1. J Antimicrob Chemother. 1983 Sep;12 Suppl B:79-88 - PubMed
    1. Sex Transm Dis. 1985 Jan-Mar;12(1):55-6 - PubMed

Publication types